ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
Q2 FY27 revenue up 28% and PAT up 26%, but EBITDA rose only 3% as margin fell to 18%. Management's FY27 outlook is qualitative; no growth number was given.
Q2FY27 revenue ₹752 Cr (+28% YoY) and PAT ₹64 Cr (+26%). EBITDA margin fell to 18% (23% YoY) on raw material costs. Derivatives & Specialty now 57% of revenue. CPVC and ECH capacity due Q3FY27.
Epigral reported Q2 FY27 PAT of ₹64 Cr, up 26% YoY, with revenue at ₹752 Cr. EBITDA margin was 18% despite elevated raw material costs.
Epigral Ltd reported revenue from operations of ₹746 Cr (+27.0% YoY) and net profit of ₹65.1 Cr (+27.1% YoY) for Q2 FY27.
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Epigral received a Rs.28.11 crore income tax demand for AY 2023-24, including interest. The company considers the demand unmaintainable and is filing an appeal.
Epigral schedules a board meeting on November 2, 2026 to approve unaudited Q2 and half-year results ended September 30, 2026. The notice is issued for shareholder information.
Epigral Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, regarding security dematerialization for the quarter ended September 30, 2026.
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
Epigral Limited plans to establish a new manufacturing facility for Epoxy Resin and Multi-Purpose Plant at Dahej, Gujarat. The project requires an investment of ₹600 Crore.
Epigral Ltd reported revenue from operations of ₹705.4 Cr (+16.3% YoY) and net profit of ₹99.7 Cr (-38.0% YoY) for Q1 FY27.
Epigral Ltd scheduled a board meeting for July 27, 2026. The board will consider the company's first quarter unaudited financial results.
Epigral Limited clarified that recent volume and price movements are due to market conditions. The company confirms no undisclosed price-sensitive information exists.
Epigral Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026. The report details the distribution of shareholdings among various investor categories.
CRISIL reaffirmed Epigral Limited's long-term rating at AA/Stable and short-term rating at A1+. The ratings cover bank loan facilities worth Rs. 1050 Crore.
Epigral Limited incorporated a wholly-owned subsidiary, Epigral Advanced Materials Limited, for chemical manufacturing. The subsidiary has a paid-up capital of Rs. 1 lakh.
Epigral Limited concluded its 19th AGM on June 08, 2026. Shareholders approved six resolutions, including adoption of financial statements and declaration of a ₹5.00 final dividend.
CRISIL reaffirmed Epigral Limited's long-term rating at AA/Stable and short-term rating at A1+. The assessment covers bank loan facilities totaling ₹1050 Crore.
Epigral Limited announced the successful passage of special resolutions via postal ballot for director re-appointments. Members approved all items with requisite majority through remote e-voting.
Epigral Limited set June 01, 2026, as the record date for final dividend payment. The dividend remains subject to shareholder approval at the upcoming AGM.
Epigral achieved highest-ever quarterly revenue of ₹736cr in Q4FY26 with 23% EBITDA margins, driven by 15% volume growth and improved plant utilization.
Epigral achieved record Q4 revenue driven by 15% volume growth, though full-year profits were dragged by earlier operational headwinds and suppressed pricing.
Epigral delivered record quarterly revenue of ₹736cr, driven by a 15% QoQ volume surge and plant stabilization after major maintenance, despite geopolitical volatility.
Epigral Limited's Board has recommended a final dividend of ₹5 per equity share for the financial year 2025-2026. The record date and book closure details will be announced later. This distribution reflects the company's commitment to sharing profits with shareholders following its board meeting on May 2, 2026.
Epigral Ltd reported record Q4FY26 revenue of ₹736 Crore, up 17% year-on-year, driven by volume growth and improved realizations. The Board proposed a final dividend of ₹5 per share. While PAT stood at ₹82 Crore, EBITDA margins improved to 23%. The company continues its strategic capex expansions in CPVC and Epichlorohydrin capacities.
Epigral Limited delivered record Q4FY26 revenue of ₹736 Cr (up 22% QoQ) with EBITDA margins improving to 23%. Strategy focuses on transitioning towards a 70% high-margin Derivatives & Specialty revenue mix by FY28.
Epigral reported record Q4FY26 revenue of ₹736 Cr (up 22% QoQ) with 23% EBITDA margins. Growth driven by volume recovery and higher contribution (54%) from derivatives and specialty chemicals.